Journal
ALLERGY
Volume 68, Issue 12, Pages 1509-1519Publisher
WILEY
DOI: 10.1111/all.12324
Keywords
atopic dermatitis; chronic urticaria; drug allergy
Categories
Funding
- ALK-Scherax
- Amgen
- Astellas
- Basilea
- Bayer
- Biocon
- Galderma
- GlaxoSmithKline
- Hickma
- Janssen
- Karrer
- L'Oreal
- MEDA
- Merck-Sharp-Dohme
- Novartis
- Pierre-Fabre
- Roche
- Therakos
Ask authors/readers for more resources
During the last few years, an impressive amount of experimental studies and clinical trials have dealt with a variety of distinct topics in allergic skin diseases - especially atopic dermatitis. In this update, we discuss selected recent data that provide relevant insights into clinical and pathophysiological aspects of allergic skin diseases or discuss promising targets and strategies for the future treatment of skin allergy. This includes aspects of barrier malfunction and inflammation as well as the interaction of the cutaneous immune system with the skin microbiome and diagnostic procedures for working up atopic dermatitis patients. Additionally, contact dermatitis, urticaria, and drug reactions are addressed in this review. This update summarizes novel evidence, highlighting current areas of uncertainties and debates that will stimulate scientific discussions and research activities in the field of atopic dermatitis and skin allergies in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available